Council Members in this Study Group: 92
This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.
Leading institutions connect with members of this Study Group through GLG
John WaughDirector of System Laboratory Operations
HENRY FORD HEALTH SYSTEM![]()
John Waugh is the Director of System Laboratory Operations at Henry Ford Health System, one of the top ten US laboratories in size. In this research and academic medical center in Detroit, Mr. Waugh has expertise in new and emerging clinical and molecular...
Stan SchofieldManaging Principal
The Compass Group, Scarborough![]()
Stan Schofield, MS, MHA, MT (ASCP), is President of NorDx, a regional laboratory corporation which is part of the Maine Health System. He also serves as a Vice President and senior member of the health system executive management team. Mr. Schofield is...
B. Michael SilberChief of Drug Discovery R&D and Professor
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO![]()
Michael Silber, PhD, is Professor of Neurology, Bioengineering and Therapeutic Sciences, and Chief of Drug Discovery R & D, at the Institute for Neurodegenerative Diseases, UCSF School of Medicine. He has 25 years of experience as a senior leader in Pharma...
Senior Marketing Manager
THERMO FISHER SCIENTIFIC INC.![]()
Diab Elmashni, MBA, is a Senior Marketing Manager at Thermo Fisher Scientific responsible for all the global strategic marketing and product management of a 50 million dollar liquid chromatography and mass spectrometry division. He manages a team of marketing...
Gregory KhitrovDirector of Personalized Medicine Program
MOUNT SINAI SCHOOL OF MEDICINE OF![]()
Greg Khitrov, PhD, is the Director of Institutes for Personalized Medicine Core Laboratory, Director of Biobank and an Assistant Professor of Medicine at the Mount Sinai School of Medicine in New York. He has expertise in molecular biology; proteomics;...
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
the way to go, the alternative fuil future is now
March 19, 2009
Toyota to develop affordable hybrid vehicle | www.marketwatch.com
Starting to work on slowing down our dependence on foreign oil
February 13, 2009
Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics | www.tmcnet.com
The ability of pharma and biotech to leverage the rapid expansion in our knowledge base on cell surface, nuclear and cytoplasmic signaling and messaging systems has and will continue to produce novel targeted molecules. To identify which patients will respond and potential surrogate markers for the assessment of a molecule's success will require reagents that are applied to histologic sections. These capabilities, combined with imaging and data reduction of the stained sections, should be anticipated to provide a very lucrative market for companies in this diagnostic arena and to facilitate the timely introduction of effective novel markers.
Industry leaders need to work with the US Patent and Trademark office to keep US patents strong
April 24, 2008
Federal Court Sides With GlaxoSmithKline, Strikes Down Rules Issued by Patent Office | biz.yahoo.com
The USPTO is facing an epidemic amount of frivolous patents. This degrades their ability to review strong and potentially important patents in a timely manner. Although this particular change was struck down in Federal court, industry leaders need to work with the USPTO in order to strengthen the US patent system.
CooperVision enters US market with Avaira™ two-week silicone hydrogel contact lenses
April 16, 2008
CooperVision Introduces Avaira™ Two-Week Silicone Hydrogel Contact Lenses | www.coopervision.com
I’m not so sure that this is a leap forward for CooperVision. After long delays for the release of the Biofinity lens, a two-week version has just been released. The material properties are reportedly “nice”, but certainly scaled back from what was reportedly achieved with Comfilcon A.
Novel molecules and diagnostic tests
February 19, 2008
Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Diagnostic tools are availible to identify these adverse effects at an early stage in their clinical development. These tools should mitigate the seriousness of these adverse events.
June 26, 2008 | Palo Alto
GLG Seminar: Molecular Platforms and Laboratory TechnologyApril 26, 2007 | New York
GLGi: Genotyping TechnologiesLeading Experts in Users of Mass Spectrometers in the U.S. have not participated in any GLG webcasts.